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Abstract
Background. Few studies have evaluated the prevalence of severe hyperkalaemia in unselected
patient populations. We identiﬁed all episodes of severe hyperkalaemia occurring in 1 year, and de-
scribed patient demographics, clinical response and outcome. We also assessed junior doctor
knowledge of its causes and signiﬁcance.
Materials and methods. A retrospective interrogation of the database of the regional biochemical
laboratory identiﬁed all episodes of severe hyperkalaemia (K≥ 6.5 mmol/L) occurring in 2011. The
understanding of trainee doctors of the importance, causes and treatment of severe hyperkalae-
mia was assessed by structured questionnaire.
Results. Severe hyperkalaemia was recorded in 433 samples (365 patients) giving a prevalence of
0.11%. Thirty-six per cent of episodes occurred in patients under the care of a nephrologist, who
were signiﬁcantly younger than those not under the care of a nephrologist. In the nephrology
cohort, 86% occurred in patients with chronic kidney disease (CKD), the majority of which had CKD
Stage 5. In the non-nephrology cohort, only 65% occurred in the context of CKD, which was
equally distributed between Stages 3 and 5 CKD. In both patient groups, roughly 50% of episodes
occurred in association with acute kidney injury (AKI). Acute mortality (death within 48 h of docu-
mented severe hyperkalaemia) was higher in the non-nephrology compared with the nephrology
cohort. Time to repeat serum potassium was inﬂuenced by the clinical setting with shorter time to
repeat for acute care compared with ward settings. Assessment of trainee doctor’s knowledge
suggested signiﬁcant deﬁciencies in relation to severe hyperkalaemia.
Conclusions. The prevalence of severe hyperkalaemia was low and occurred predominantly in the
context of CKD and/or AKI. The majority of episodes occurred in patients not under the care of a
nephrologist. Variability in time to repeat serum potassium levels suggested deﬁciencies in care,
and assessment of trainee doctor’s knowledge suggests the need for further educational initiatives
to highlight its importance.
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Introduction
Hyperkalaemia is a potentially life-threatening condition
due to the risk of ventricular arrhythmias and cardiac
arrest when serum K+ is severely elevated [1, 2]. It is re-
ported to be a common occurrence in hospitalized
patients with an incidence of 1.1–10 patients per 100 hos-
pitalized [3–5]. These studies, however, date back over 20
years. More recent studies have focused on hyperkalaemia
in either speciﬁc disease cohorts or in hospitalized
patients only [6]. It is well established that a major cause
of hyperkalaemia is chronic renal injury with the associ-
ated interference with potassium excretion. Other high-
risk cohorts which have been studied are patients with
diabetes mellitus or congestive cardiac failure often super-
imposed on renal dysfunction and often aggravated or
precipitated by medications interfering with potassium
homeostasis [7–11]. Few recent studies however have
examined the nature of severe hyperkalaemia in an unse-
lected patient population. Due to changes in the demo-
graphics of the population and patients, and changes in
drug prescribing patterns, it is likely that the causes and
therefore the demographics of patients with hyperkalae-
mia have changed. We therefore sought in an unselected
patient cohort to examine a consecutive series of hyper-
kalaemic patients identiﬁed from the biochemical records
of all patients who had a measurement of serum potass-
ium as part of a ‘routine’ request for measurement of
‘urea and electrolytes’ in a single health board in the UK.
A previous study of 35 adult hyperkalaemic hospitalized
patients suggested that hyperkalaemia is generally mild
(>5.5<6.5 mmol/L) and therefore not a contributor to
patient mortality [11]. The adverse effects of hyperkalaemia
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on cardiac function are however concentration depen-
dent. In recognition of this, we have collected data on
patients with severe hyperkalaemia, deﬁned as a serum
potassium value of ≥6.5 mmol/L, as this level of potass-
ium leads to telephone notiﬁcation of the result to the
clinical team looking after the patient. In addition to de-
scribing the basic characteristics of patients with severe
hyperkalaemia, in contrast to previous studies we have
also collected information of patient outcome and man-
agement according to the clinical area in which the
episode of severe hyperkalaemia occurred. In light of pre-
vious studies, and also the ﬁndings of our study which
have suggested that response by clinicians to hyperkalae-
mia is frequently suboptimal, in the second component of
this study, we assessed the knowledge base of non-
specialist/non-nephrology trainee medical staff within the
hospital.
Materials and methods
Deﬁning a cohort of patients with severe hyperkalaemia
The Medical Biochemistry Department database of the
Cardiff and Vale University Health Board (serving a popu-
lation of 466 000) was interrogated to gather retrospec-
tively all serum potassium results requested for adult
patients between 1 January and 31 December 2011. Using
this database, we identiﬁed all patients over 18 years of
age, who during 2011 had a serum potassium measure-
ment ≥6.5 mmol/L. The reference range for our laboratory
is 3.5–5.3 mmol/L. Sample requests generated from inten-
sive care units or dialysis units were excluded.
Baseline serum creatinine values were sought from
the same database for each patient, up to 3 months
prior to the hyperkalaemic episode, and using the modi-
ﬁcation of diet in renal disease formula, the estimated
baseline GFR was calculated. Patients with a baseline
eGFR of ≤60 mL/min were classiﬁed as having pre-exist-
ing chronic kidney disease (CKD). In addition, the serum
creatinine measurement taken at the time of the docu-
mented episode of severe hyperkalaemia was recorded
and used to document the association of hyperkalaemia
with acute kidney injury using the acute kidney injury
network deﬁnition [12]. Electronic patient records were
used to extract all documented comorbidities recorded
for each patient prior to and up to the episode of severe
hyperkalaemia.
Assessment of the knowledge base of non-specialist
trainee medial staff
A questionnaire was distributed to trainee medical staff at
two base hospitals served by the regional renal unit. The
key areas covered by the questionnaire were signiﬁcance,
causes and treatment of hyperkalaemia (Table 4). The
purpose of the questionnaire was explained by one of
the co-authors and the questionnaire completed ‘on the
spot’. Responses were evaluated against a panel of pre-
deﬁned ideal answers, with a maximum score of 33.
Responses were collated and analysed according to the
speciality of the junior doctor and also performance of the
individual questions.
Statistical analysis was carried out by Student’s t-test,
χ2-test and one-way ANNOVA as appropriate, and P < 0.05
was deemed statistically signiﬁcant.
Results
During the 12-month period of data analysis, a total of 383
422 requests were made for the measurement of serum
electrolytes (excluding paediatrics, intensive care and dialysis
units). In the same time period, severe hyperkalaemia with
potassium values of ≥6.5 mmol/L was recorded in 433
samples (in a total of 365 patients) giving an overall preva-
lence for severe hyperkalaemia of 0.11%.
Nephrology cohort
Of the patients with severe hyperkalaemia 36% occurred
in patients under the care of nephrology, which represents
194 episodes. In the nephrology cohort, severe hyperka-
laemia was documented in patients on the general ne-
phrology ward in 56%, renal transplant unit (RTU, not
exclusively transplant patients) in 28%, and in the outpati-
ent department in 16% of the episodes.
The average age of this nephrology cohort was 57.9
years (95% CI 55.0–60.8 years), reﬂecting the fact that the
majority (67%) of the patients in this nephrology cohort
where <65 years of age (Figure 1A). There was no differ-
ence in the age of the male and female patients within
this cohort (Table 1). In 86% of the patients, severe hyper-
kalaemia occurred in the context of CKD (Table 2), and of
those with CKD, 65% were classiﬁed as Stage 5 CKD
(Figure 1B). As might be expected given the known higher
incidence of CKD in males, there was a higher prevalence
of male (61%) compared with female (39%) patients in
the nephrology cohort with severe hyperkalaemia.
In this nephrology cohort, severe hyperkalaemia associ-
ated with AKI (as deﬁned by the AKI network, dependent
on change in creatinine, and including both AKI and acute
on chronic kidney injury) occurred in 54% of the patients
(Table 2). Within this group, AKI on a background of CKD
represents 79% of patients classiﬁed as having AKI. The
documented incidence of severe hyperkalaemia in the
context of AKI was no different between the two ward set-
tings, RTU 57% versus Gen Neph 59%, P = 0.9). Only a
small minority of patients in the nephrology cohort had a
documented episode of severe hyperkalaemia in the
absence of either CKD or AKI (3/132 = 2%).
Non-nephrology cohort
Of all the severe hyperkalaemic events, 239 were recorded in
a total of 233 patients not under the care of a nephrologist,
thus representing 64% of all the severe hyperkalaemic epi-
sodes. Severe hyperkalaemia in the non-nephrology cohort
occurred in the setting of acute admissions in 35% and non-
acute wards in 52% (medical ward 34%, surgical ward 17%)
of the episodes. The remainder of the hyperkalaemic epi-
sodes occurred either in the context of the hospital outpati-
ent department (nine patients) or following investigations
requested by a primary care physician (three patients).
This non-nephrology cohort was signiﬁcantly older than
the nephrology cohort (Table 1) with an average age of
71.2 years (95% CI 69.8–73.7 years, P < 0.0001 versus
nephrology). In contrast to the nephrology cohort, in the
non-nephrology cohort, the prevalence of hyperkalaemia in-
creased with age (Figure 1A). As with the nephrology cohort,
there was a predominance of male patients (male = 54%,
female = 47%, P = 0.14 compared with the distribution in
the nephrology cohort). In 65% of the patients, severe hy-
perkalaemia occurred in the context of CKD (Table 2), which
was signiﬁcantly lower than the proportion with CKD in the
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nephrology cohort (P < 0.0001). Unlike the nephrology
cohort, the patients were distributed equally across all CKD
stages (Figure 1B). Within the non-nephrology cohort, the
patients with CKD and hyperkalaemia were signiﬁcantly
older than those with no CKD and hyperkalaemia (CKD 75.2
years 95% CI 73.2–77.3 years versus non-CKD 65.4 years
95% CI 61.6–69.2 years, P < 0.0001).
In this non-nephrology cohort, hyperkalaemia occurred
in the context of AKI in 51% of patients (Table 2) which is
no different to the proportion of hyperkalaemic patients
with AKI in the nephrology cohort (P = 0.4). In the non-ne-
phrology cohort, 61% of those with AKI (73/119) occurred
in the context of pre-existing CKD. The distribution of hy-
perkalaemic patients with CKD was equal between the
group with AKI 61% and no AKI 52% (P = 0.5).
Unlike the cohort under the care of nephrology in the
non-nephrology cohort, a signiﬁcant proportion of severe
hyperkalaemic episodes (15%) was documented in
Fig. 1. Prevalence (%) of severe hyperkalaemia in patients under the care of a nephrologist (solid line) or not under the care of a nephrologist (broken line)
by age (A). eGFR interval (B) and serum potassium (C).
Table 1. Basic demographics of patients with severe hyperkalaemia
Total Females Males
Nephrology cohort
Number of patients (%) 132 51 (39) 81 (61)
Average age (years) 57.9 (95% CI 55.0–60.8) 57.6 (95% CI 53.3–61.9) 58.1 (95% CI 54.4–61.9)
Non-nephrology cohort
Number of patients (%) 233 108 (46) 125 (54)
Average age (years) 71.2 (95% CI 69.8–73.7) 71.2 (95% CI 68.5–73.9) 71.2 (95% CI 68.5–73.9)
Table 2. Association of severe hyperkalaemia with CKD and AKI
Nephrology cohort Non-nephrology cohort
Association with CKD 114 of 132 151 of 233 P < 0.0001
Association with AKI 71 of 132 119 of 233 P = 0.04
Association with acute-on-chronic renal injury 56 of 71 73 of 119 P = 0.01
No CKD and No AKI 3/132 35 of 233 P < 0.0001
Mean K+ mmol/L 6.9 (95% CI 6.8–6.92) 7.0 (95% CI 6.9–7.1) P = 0.003
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patients with neither CKD nor AKI (35 of 233 versus 3/132
in the Neph cohort (P < 0.001), such that roughly half of
those with normal renal function were hyperkalaemic in
the absence of AKI.
Despite the difference in the patient demographics
between the nephrology and non-nephrology cohort, the
distribution of serum potassium values was similar in the
nephrology and non-nephrology cohorts (Figure 1C). However,
the mean potassium value in the non-nephrology cohort was
signiﬁcantly higher than in the nephrology cohort (non-Neph
7.0 mmol/L 95% CI 6.9–7.1 versus Neph 6.9 mmol/L 95% CI
6.8–6.92, P = 0.003).
Associated co-morbidities
Table 3 shows the comparison of comorbidities recorded
for the severe hyperkalaemic patients in the nephrology
and non-nephrology cohorts. The burden of comorbidity
was higher in the non-nephrology cohort, with a mean
number of 2.3 morbidities per patient compared with 1.9
in the nephrology cohort. Speciﬁcally, the incidence of all
forms of heart disease (43.8 versus 31.9%, 4 P = 0.022),
peripheral vascular disease (12.4 versus 1.4%, P = 0.0001)
and a recorded diagnosis of malignancy (25.7 versus
14.6%, P = 0.01) was signiﬁcantly more common in the
non-nephrology cohort. There was no statistical difference
in the incidence of hypertension (49.4 versus 56.9%, P = 0.1)
or diabetes (35.2 versus 36.1%) between the two cohorts. In
the non-nephrology, the incidence of severe hyperkalaemia
associated with diabetes (P = 0.01), hypertension (P = 0.04)
and heart disease (0.0002) was signiﬁcantly lower in the
cohort of patient with neither CKD nor AKI.
Outcome/management
Time to repeat potassium was taken as an indication of
the response to the laboratory generated alert of severe
hyperkalaemia.
Nephrology cohort. For the nephrology cohort, repeat
measurement was undertaken in 188 of 192 episodes.
Overall, in patients with severe hyperkalaemia and in
which a repeat measurement was recorded, 37% were re-
peated on the same day as the hyperkalaemic episode
and a further 41% on the following day. As expected, the
time to repeat the potassium measurement in the OPD
was longer than on either of the ward settings (OPD
12.2 ± 34.6, Gen Neph 3.92 ± 14.9, transplant, 2.76 ± 15.7,
data presented as mean number of days ± SD, one-way
ANNOVA P = 0.08).
There were three patient deaths within 48 h of docu-
mentation of hyperkalaemia, and in two of these no
repeat measurement was available (in these two patients,
the measured serum potassium was 6.7 and 6.6 mmol/L,
and occurred in the context of patients with known CKD
and an eGFR of 14 and 4 mL/min, respectively).
Non-nephrology cohort. Overall, in patients with severe
hyperkalaemia and in which a repeat measurement was
Table 3. Documented comorbidities of patients with severe hyperkalaemia
Non-nephrology cohort Nephrology cohort
Whole
group % (n)
CKD No
AKI % (n)
CKD +AKI
% (n)
No CKD
No AKI %
(n)
No CKD
+AKI % (n)
Whole
group %
(n)
CKD
No AKI %
(n)
CKD +AKI
% (n)
No CKD
No AKI
% (n)
No CKD
+AKI % (n)
Atrial ﬁbrillation 24 (55) 30.4 (24) 19.4 (14) 13.9 (5) 26.1 (12) 9.7 (14) 16.7 (5.1) 5.1 (3) 0 0
Congestive
cardiac failure
17.2 (40) 17.2 (14) 22.2 (16) 5.6 (2) 17.4 (8) 8.3 (12) 7.6 (5) 8.5 (5) 0 13.3 (2)
Ischemic heart
disease
27 (62) 38 (30) 27.8 (20) 8.3 (3) 19.6 (9) 24 (34) 25.8 (17) 28.8 (17) 0 0
Valvular heart
disease
7.3 (17) 7.6 (6) 11.1 (8) 5.6 (2) 2.2 (1) 4.2 (6) 6.1 (4) 3.4 (2) 0 0
Cerebrovascular
disease
11.6 (27) 8.9 (7) 18.1 (13) 0 15.2 (7) 1.4 (2) 3.0 (2) 0 0 0
Peripheral
vascular disease
12.4 (29) 5.1 (4) 27.8 (20) 2.8 (1) 8.7 (4) 1.4 (2) 1.5 (1) 1.7 (1) 0 0
Hypertension 49.4 (115) 49.4 (39) 59.7 (43) 30.6 (11) 47.8 (22) 56.9 (82) 45.5 (30) 67.8 (40) 50 (2) 66.7 (10)
Diabetes 35.2 (82) 32.9 (26) 44.4 (32) 13.9 (5) 41.3 (19) 36.1 (52) 34.8 (23) 37.3 (22) 25 (1) 40 (6)
Hyperlipidaemia 10.3 (24) 13.9 (11) 11.1 (8) 2.8 (1) 8.7 (4) 9.7 (14) 4.5 (3) 11.9 (7) 25 (1) 20 (3)
Pulmonary
disease
12.0 (28) 15.1 (12) 9.7 (7) 8.3 (3) 13.0 (6) 6.3 (9) 7.6 (5) 6.8 (4) 0 0
Liver disease 4.7 (11) 2.5 (2) 1.4 (1) 5.6 (2) 13.0 (6) 2.8 (4) 0 6.7 (4) 0 0
Thyroid disease 6.9 (16) 11.4 (9) 1.4 (1) 5.6 (2) 8.7 (4) 4.9 (7) 3.0 (2) 5.1 (3) 0 13.3 (2)
Malignancy 25.7 (60) 17.7 (14) 27.8 (20) 38.9 (14) 26.1 (12) 14.6 (21) 16.7 (11) 15.2 (9) 0 6.7 (1)
No recorded
comorbidity
7.7 (18) 5.1 (4) 6.9 (5) 16.7 (6) 6.5 (3) 6.9 (10) 1.5 (1) 11.9 (7) 25 (1) 6.7 (1)
No data available 4.3 (10) 2.8 (4)
Table 4. Score of attitude- and knowledge-based assessment by speciality of responding junior doctor
Total Med Surg A&E GP Anaes O&G Paeds
N 190 71 47 7 10 18 7 10
Average score ± SD 17.3 ± 5.1 19.3 ± 4.4 16.5 ± 5.2 16.4 ± 5.6 15.8 ± 2.9 19.2 ± 4.9 12.3 ± 6.6 15.8 ± 2.9
% 52.6 58.6 50.0 49.8 47.9 58.2 37.2 47.9
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recorded, 45% were repeated on the same day as the
hyperkalaemic episode and a further 35% on the following
day. When separating the time to repeat potassium
measurement by clinical setting, there was a signiﬁcant
difference in time to repeat (acute care 0.6 ± 0.89, ward
3.7 ± 20.6, OPD 57.3 ± 101.4, data presented as mean
number of days ± SD, one-way ANNOVA P < 0.0001) and
direct comparison also demonstrated a signiﬁcant difference
when comparing the time to repeat measurement in the
acute care settings and the two (medical and surgical) non-
nephrology ward settings (P = 0.05). There was no signiﬁcant
difference in time to repeat between nephrology ward and
non-nephrology wards. As would be expected, the time to
repeat potassium measurement in either the OPD (57 ± 110
days, n = 9) setting or in general practice (12 ± 11 days, n = 3)
was longer than in either the acute or ward setting; however,
as only a small number of patients had documented severe
hyperkalaemia in these two settings, a meaningful statistical
analysis was not appropriate.
In the non-nephrology cohort, 23 patients with docu-
mented severe hyperkalaemia had no record of a repeat
measurement of potassium, which is signiﬁcantly more
than in the nephrology cohort (P = 0.002). For the non-ne-
phrology cohort, there were 36 deaths within 48 h of docu-
mented severe hyperkalaemic event (distributed equally
between acute care and ward settings), which was signiﬁ-
cantly greater than the acute (<48 h) mortality in the ne-
phrology cohort (P < 0.0001). Of these 36 ‘acute deaths’
with severe hyperkalaemia, 26 were also associated with
AKI. In these 36 patients, 18 (50%) had no repeat measure-
ment, compared with a ‘no-repeat rate’ of 14% (2/14) for
patients who survived >48 h but who died within 7 days of
a severe hyperkalaemic episode (P = 0.017). The mean pot-
assium for those who died within 48 h was greater than
those who died >48 h but <7 days, 7.22 mmol/L (95% CI
6.95–7.48) versus 6.85 mmol/L (95% CI 6.62–70.9, P = 0.5).
Attitudes and knowledge
Having highlighted differences in the response to severe
hyperkalaemia in different clinical settings, we next
sought to assess the working knowledge of doctors in all
sub-consultant grades in terms of diagnosis and manage-
ment. Questionnaires were completed by 190 trainees: 77
foundation, 51 core and 59 specialty trainees. Of those
completing the questionnaires, 37% were physicians and
a further 25% working in surgical specialities.
Table 4 gives the overall score (out of a possible 33) and
scores broken down by specialities. For the whole cohort,
the overall score was 17 (52.5%). There was however a sig-
niﬁcant difference across the specialities, with the
medical specialities and anaesthetic trainees scoring sig-
niﬁcantly higher than the other trainees (P = 0.00001 one-
way ANNOVA).
Table 5 gives the mean score of each of the questions.
There was a signiﬁcant difference in the performance of the
individual questions (P < 0.00001 one-way ANNOVA), with
the lowest scores obtained for the knowledge of the normal
range of serum potassium, threshold for treating hyperkalae-
mia and knowledge of drugs which lead to hyperkalaemia.
Discussion
Overall, the incidence of severe hyperkalaemia in this un-
selected patient cohort was low. Although the incidence
was lower than reported in the widely cited literature,
which is now >20 years old [3–5], it is similar to the more re-
cently reported incidence of severe hyperkalaemia (≥6.3
mmol/L) of 0.8% in a study of all K+ assays run by a single
laboratory [13], with the discrepancy likely to be attribu-
table to the fact that the study was conﬁned to hospitalized
patients, whereas we have analysed all samples irrespec-
tive of the source of the request.
Although severe hyperkalaemia is commonly associated
with renal impairment and therefore may be considered to
lie within the domain of the nephrologist, it is of note that
in our study, severe hyperkalaemia was more common in
the non-nephrology cohort. Our study also conﬁrms that
the vast majority of severe hyperkalaemia occurs in the
context of a hospital admission, with only 4.6% (11 of 239)
hyperkalaemic events documented in a non-hospital
environment (either OPD or primary care) in the non-ne-
phrology cohort. Furthermore, even in those patients under
the care of a nephrologist, severe hyperkalaemia was only
seen in the outpatient setting in a small minority (16%).
Severe hyperkalaemia occurring in the nephrology and
non-nephrology cohorts affects very different patient
groups. For the nephrology cohort, severe hyperkalaemia
tended to occur in a younger patient group and in the
context of end-stage renal failure, whereas in the non-ne-
phrology cohort, severe hyperkalaemia occurred in an older
patient cohort and across all stages of renal disease. The
high proportion of patients with CKD in the nephrology
cohort is likely to account for the higher number of
recurrent episodes of severe hyperkalaemia in the nephrol-
ogy group with 194 episodes occurring in only 132 patients.
In both groups, although severe hyperkalaemia was
associated with CKD in the majority, the proportion associ-
ated with CKD in the non-nephrology cohort was smaller.
Table 5. Score of attitude and knowledge based assessment by speciality question
Question number (marks possible)
Mean score
(±SD)
% of maximum
possible score
Q1: What is the normal range for K in your hospital (1 mark) 0.16 ± 0.4 16.4
Q2: What level of K would you treat (2 marks) 0.45 ± 0.6 22.5
Q3: What are the ECG changes associated with hyperkalaemia (3 marks) 1.95 ± 0.8 65.1
Q4: Name ﬁve drugs causing hyperkalaemia (5 marks) 2.2 ± 1.2 44.6
Q5: Other than drugs give four other causes of hyperkalaemia (4 marks) 2.1 ± 0.9 51.6
Q6: What are key clinical assessments required in hyperkalaemic patients (2 marks) 1.3 ± 0.6 64.0
Q7: List the initial investigations of a severely hyperkalaemic patients (3 marks) 1.9 ± 0.7 65.1
Q8 (a) Name the treatment options for a patient with severe hyperkalaemia (5 marks). (b) What is the mode
of action of the listed treatment? (5 marks)
3.3 ± 1.2 66.5
2.3 ± 1.5 46.2
Q9: What would you consider to be indications for referral to a nephrologist? (3 marks) 1.7 ± 0.9 57.1
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This might suggest that the contribution of medication to
severe hyperkalaemia may be greater in this cohort. Due to
the retrospective nature of the study, wewere unable to de-
termine medications prescribed at the time of documen-
tation of hyperkalaemia. We were able to collect data on
recorded comorbidities which are likely to indicate indirectly
the prescription of medication which may potentially cause
or aggravate hyperkalaemia. It is of note that there was a
signiﬁcantly higher burden of comorbidities in the non-ne-
phrology cohort consistent with a higher rate of prescrip-
tion of medication likely to pre-dispose to hyperkalaemia.
This would be further supported by the signiﬁcant pro-
portion of episodes of severe hyperkalaemia in the non-ne-
phrology cohort which occurred in the absence of either
CKD or AKI. In this cohort, however, the incidence of severe
hyperkalaemia was signiﬁcantly lower in absence of renal
disease and particularly in those with hypertension, heart
disease or diabetes, groups which are likely to have a high
burden of medication, suggesting that the most important
factor is renal function and that mediation is likely to be an
aggravating factor rather than the sole determinant of
severe hyperkalaemia in the majority of patients.
Although as one might predict severe hyperkalaemia in
the context of CKD was more common in the nephrology
cohort, over two-thirds of patients in the non-nephrology
cohort also experienced severe hyperkalaemia on a back-
ground of CKD. Much has been made of the role of the ne-
phrologist in the care of patients with CKD, with initiatives
such as automated eGFR reporting launched to highlight
patients with modest degrees of CKD. Despite increasing
numbers of patients being referred to a nephrologist
following implementation of automated eGFR reporting
[14–19], it is clear that only a minority of patients with
CKD are seen by a nephrologist [20]. The large group of
patients with CKD who are not under the care of a ne-
phrologist remains a challenge. In our study, within the
cohort of patients with severe hyperkalaemia, the mean
serum potassium was lower in the nephrology cohort. This
may be a further reﬂection of the beneﬁt of early nephrol-
ogy input, medication review and appropriate dietetic
input [21]. As ∼5% of the adult population have moderate
to advanced CKD [22, 23], clearly, referral of all patients
would be inappropriate and, furthermore, nephrology ser-
vices would be swamped [24]. The challenge therefore is
to carefully select patients who are likely to most beneﬁt
from nephrology care such as those with rates of change
of eGFR >5 mL/min/year or those with factors which need
added input such as uncontrolled hypertension. To this, it
may also be appropriate to add patients who are suscep-
tible to hyperkalaemia.
The association of severe hyperkalaemia with AKI is to
be expected. In both of our patient groups, severe hyper-
kalaemia was associated with AKI in over half of the epi-
sodes. As with CKD, this suggests that a large proportion
of patients with AKI is not seen by a nephrologist. Im-
proved outcomes following AKI have been reported even
with minor degrees of AKI following specialist input [25].
Although the primary intention in carrying out this work
was to focus on demographics and management of
severe hyperkalaemia, the data also highlight a large
cohort of patients with AKI and associated signiﬁcant
metabolic disturbance who are not under the care of
nephrology.
The retrospective nature of the study prevented us from
directly examining any interventions. We therefore used
the time to repeat serum potassium measurement as a
marker of awareness of the signiﬁcance and also of action
taken following notiﬁcation of the abnormal result. The
number of patients with no documented repeated mea-
surement of serum potassium was higher in the non-
nephrology patient group than the nephrology group.
Acute mortality, deﬁned for the purposes of this study as
death within 48 h of documentation of severe hyperkalae-
mia was low in the nephrology cohort. In contrast, in the
non-nephrology cohort, there were 36 deaths giving an
acute death rate of 15%. Within this group, it is of note
that compared with the whole group there was a dispro-
portionately high proportion of patients who did not have
a repeat measurement of serum potassium. We were
however unable to determine cause of death nor the con-
tribution of hyperkalaemia to the agonal event. It is of
note however that a documented diagnosis of malignancy
was more common in this group furthermore the burden
of comorbidity being higher in this group would also
suggest a sicker patient cohort to begin with. Without
access to patient records, we were, however, unable to de-
termine if the lack of repeated measurement of potassium
reﬂects a conscious decision not to repeat the measure-
ment in a group of sick patients with a higher incidence of
‘terminal illness’. Given that in 50% of the acute deaths,
no repeat serum potassium was undertaken, it is likely
however that at least in some of these cases, the severe
hyperkalaemic episode was at least a contributing factor
in the adverse patient outcome.
The medical management of hyperkalaemia is well
described, and their relative effectiveness in terms of
reduction in serum potassium has been recently reported
[26]. In our study, for patients in which repeat potassium
measurements were undertaken, it was apparent that the
clinical area in which the event occurred affected the time
to repeat measurement, with the time to repeat being sig-
niﬁcantly longer on all ward areas compared with the
acute care settings. In the context of our hospital setting,
acute care is characterized by early and repeated consult-
ant/senior review, whereas ward based care on a day-to-
day basis is directed by more junior medical staff with
senior colleague input provided by structured formal
wards rounds occurring two or three times per week with
additional input as requested on an ad hoc basis. This
model of care and the discrepancy between times to
repeat between the two clinical care settings suggested
that these differences were at least in part driven by a lack
of appreciation of the severity of the problem by more
junior members of the medical teams. This was directly
addressed by our questionnaire of the attitudes and
knowledge of junior medical staff. Our educational survey
conﬁrmed serious gaps in knowledge of severe hyperka-
laemia. Although the results suggest a difference in
knowledge across specialities, even in the best performing
specialities overall scores revealed signiﬁcant knowledge
gaps. Of particular concern was the signiﬁcant gaps in
fundamental knowledge related directly to clinical man-
agement of patients, with questions related to threshold
and mechanisms for treatment and drugs which cause
hyperkalaemia being amongst those which performed
worst.
Summary
In summary, overall prevalence of severe hyperkalaemia
is low, with the majority of episodes occurring in hospital-
ized patients. Patients with severe hyperkalaemia under
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the care of a nephrologist are younger and tended to have
CKD5 whilst in the non-nephrology cohort severe hyperka-
laemia occurs across the whole range of renal function.
We also identiﬁed deﬁciencies in the care of patients with
severe hyperkalaemia and by the use of an educational
survey highlighted gaps in the knowledge of non-special-
ist junior doctors in their knowledge of its management.
This highlights the need to enhance the non-specialist un-
derstanding and awareness of the context and manage-
ment of severe hyperkalaemia.
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